J.B. Chemicals & Pharmaceuticals Limited has submitted its Integrated Annual Report for the fiscal year 2025-26, highlighting strong operational performance and strategic growth. The company reported a revenue of ₹4,148 crores and an 8% growth in both EBITDA and Profit After Tax (PAT). With a legacy spanning nearly five decades, J.B. Pharma continues to strengthen its domestic franchise and international footprint, reinforcing its position as a leading global manufacturer of medicated lozenges.
Financial Highlights
During the 2025-26 fiscal year, J.B. Pharma demonstrated consistent financial progress. The company achieved a total operating revenue of ₹4,148 crores. Operational efficiency was a core focus, with the Operating EBITDA growing by 8% to ₹1,178 crores. Additionally, the company reported an 8% increase in Profit After Tax (PAT), reaching ₹709 crores. The EBITDA margin stood at 28.4%, reflecting the company’s commitment to disciplined cost management and a favourable product mix.
Strategic Domestic Performance
The domestic formulations business remained a key growth driver, outperforming the Indian Pharmaceutical Market with an 11% growth rate. This success was primarily attributed to momentum in chronic therapies, particularly cardiology. The company successfully retained its #22 ranking among the top 25 companies in the Indian market, with six of its brands featuring in the Top 300 of the Indian Pharmaceutical Market (IPM). Notably, the Razel franchise crossed the significant milestone of ₹100 crores.
Operational Excellence and Global Reach
J.B. Pharma continues to leverage its eight state-of-the-art manufacturing facilities, which hold global regulatory approvals, to maintain quality and reliability. The company maintains a presence in over 40 countries, supported by 2,600+ medical representatives and a workforce of over 5,600 employees. The international and CDMO businesses delivered stable performance, with the company maintaining its status as a top 5 global manufacturer of medicated and herbal lozenges.
Strategic Alignment and Governance
A pivotal development during the year was the acquisition of a controlling stake in the company by Torrent Pharmaceuticals Limited. This partnership is expected to unlock long-term value through enhanced scale, operational efficiencies, and expanded market access. The company remains committed to sustainable growth and responsible corporate governance, as reflected in its S&P Global ESG score of 86, ranking it among the leading pharmaceutical companies globally.
Source: BSE
